Anifrolumab-fnia
Brand names: Saphnelo · Active ingredient: Anifrolumab
In short: SAPHNELO is indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy. Limitations of Use The efficacy of SAPHNELO has not been evaluated in patients with severe active lupus nephritis or severe active central nervous
What is Anifrolumab-fnia used for?
SAPHNELO is indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy.
Limitations of Use
The efficacy of SAPHNELO has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Use of SAPHNELO is not recommended in these situations.
Anifrolumab-fnia dosage
SAPHNELO is intended for use under the guidance of a healthcare provider and may be administered as an intravenous infusion or as a subcutaneous injection.
SAPHNELO vials are for intravenous use only and must be diluted prior to intravenous administration .
SAPHNELO prefilled syringe and autoinjector (SAPHNELO PEN) are for subcutaneous use only .
The recommended dosage of SAPHNELO is:
•
300 mg, administered as an intravenous infusion over a 30‑minute period every 4 weeks; or
•
120 mg, administered as a subcutaneous injection once every week.
Missed Dose
If a planned intravenous infusion is missed, administer SAPHNELO as soon as possible. Maintain a minimum interval of 14 days between infusions.
If a planned subcutaneous dose is missed, instruct the patient to administer SAPHNELO as soon as they remember. Thereafter, instruct the patient to start a new weekly schedule from the day the missed dose was administered or resume dosing on their usual day of administration, providing a minimum interval of 3 days between subcutaneous injections.
SAPHNELO is supplied as a single-dose vial. Prepare the diluted infusion solution using aseptic technique, by the following procedure:
1.Visually inspect the vial for particulate matter and discoloration. SAPHNELO is a clear to opalescent, colorless to slightly yellow, solution. Discard the vial if the solution is cloudy, discolored or visible particles are observed. Do not shake the vial.
2.Withdraw and discard 2 mL of solution from a 50 mL or 100 mL 0.9% Sodium Chloride Injection, USP infusion bag.
3.Withdraw 2 mL of solution from the vial of SAPHNELO and add it to the infusion bag. Mix the solution by gentle inversion. Do not shake.
4.Each vial is intended for one time use only. Discard any unused portion remaining in the vial.
5.Administer the infusion solution immediately after preparation.
6.If the infusion solution is not administered immediately, store the diluted solution of SAPHNELO at room temperature 59°F to 77°F (15°C to 25°C) for up to 4 hours, or refrigerated 36°F to 46°F (2°C to 8°C) for up to 24 hours. Do not freeze. Protect from light. If refrigerated, allow the diluted SAPHNELO solution to reach room temperature prior to administration.
7.Administer the infusion solution intravenously over a 30-minute period through an infusion line containing a sterile, low-protein binding 0.2 to 15 micron in-line or add-on filter.
8.To ensure the complete dose of SAPHNELO has been administered, flush the entire infusion line with 25 mL of 0.9% Sodium Chloride Injection, USP at the end of the infusion.
9.Do not co-administer other medicinal products through the same infusion line.
10.Dispose of any unused medicinal product or waste material in accordance with local requirements. …
How to take Anifrolumab-fnia — instructions & advice from the label
Advise the patient and/or caregiver to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
Serious Infections
Inform patients that SAPHNELO may decrease their ability to fight infections and that serious infections, including fatal ones, occurred in patients receiving SAPHNELO in clinical trials. Also inform patients that they are at increased risk of respiratory infections and herpes zoster during treatment with SAPHNELO . Advise patients to contact their healthcare provider if they develop any symptoms of an infection.
Hypersensitivity Reactions/Anaphylaxis
Inform patients that serious hypersensitivity reactions, including anaphylaxis, have been reported in patients who received SAPHNELO. Instruct patients to immediately tell their healthcare provider or go to the emergency department of their nearest hospital, if they experience symptoms of an allergic reaction (e.g., anaphylaxis) during or after the administration of SAPHNELO .
Immunizations
Inform patients that they should not receive live or live-attenuated vaccines while receiving SAPHNELO. …
Warnings & precautions
Do not take this medicine if: SAPHNELO is contraindicated in patients with a history of anaphylaxis with anifrolumab-fnia .
Serious and sometimes fatal infections (including COVID‑19) have occurred in patients receiving immunosuppressive agents, including SAPHNELO. In controlled trials, fatal infections occurred more frequently in patients receiving SAPHNELO .
In controlled trials, SAPHNELO increased the risk of respiratory infections and herpes zoster (disseminated herpes zoster events have been reported) .
Avoid initiating treatment with SAPHNELO in patients with any clinically significant active infection until the infection is resolved or adequately treated. Consider the benefit and risk of administering SAPHNELO in patients with a chronic infection, a history of recurrent infections, or known risk factors for infection. Instruct patients to seek medical advice if signs or symptoms of a clinically significant infection occur. If a patient develops an infection or is not responding to standard anti-infective therapy while on SAPHNELO, monitor the patient closely and consider interrupting SAPHNELO until the infection resolves.
Serious hypersensitivity reactions (including anaphylaxis) have been reported following SAPHNELO administration . Events of angioedema have also been reported .
Other hypersensitivity reactions and infusion-related reactions have occurred following administration of SAPHNELO . Consider pre-medication before infusion of SAPHNELO for patients with a history of these reactions.
SAPHNELO should be administered by healthcare providers prepared to manage hypersensitivity reactions, including anaphylaxis, and infusion-related reactions. If a serious infusion-related or hypersensitivity reaction (e.g., anaphylaxis) occurs, immediately interrupt the administration of SAPHNELO and initiate appropriate therapy. …
Anifrolumab-fnia side effects
The following clinically significant adverse reactions are also discussed elsewhere in the labeling:
•Serious Infections
•Hypersensitivity Reactions Including Anaphylaxis
•Malignancy
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adverse Reactions with Intravenous Administration
The safety of SAPHNELO was assessed in adult patients with moderate to severe SLE who received SAPHNELO 300 mg by intravenous infusion every 4 weeks (N=459) for 52 weeks, compared to placebo (N=466) in controlled clinical trials (Trials 1, 2 and 3) . The population studied had a mean age of 41 years (range: 18 to 69), of which 93% were female, 60% White, 13% Black/African American, and 10% Asian. All patients received standard therapy.
In the controlled-clinical trials, adverse reactions, irrespective of causality, were reported in 87% of patients receiving SAPHNELO and 79% of patients receiving placebo.
Adverse reactions that occurred at greater than or equal to 2% incidence are shown in Table 1. …
Drug interactions
No formal drug interaction trials have been conducted.
About this medicine
Anifrolumab-fnia is a type I interferon (IFN) receptor antagonist, immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that is produced in mouse myeloma cells (NS0) by recombinant DNA technology. The molecular weight is approximately 148 kDa.
Intravenous Infusion
SAPHNELO (anifrolumab-fnia) injection is a sterile, preservative‑free, clear to opalescent, colorless to slightly yellow, solution in a single-dose vial for intravenous use.
Each 2 mL single-dose vial contains 300 mg (150 mg/mL) of anifrolumab-fnia, histidine (3 mg), L-histidine hydrochloride monohydrate (6 mg), lysine hydrochloride (18 mg), polysorbate 80 (1 mg), trehalose (89 mg), and Water for Injection, USP. The pH is 5.9.
Subcutaneous Injection
SAPHNELO (anifrolumab-fnia) injection is a sterile, preservative-free, clear to opalescent, colorless to slightly yellow, solution in a prefilled syringe or autoinjector for subcutaneous injection. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID d6203302-2128-41a7-b0b4-0e6c0704d4dc. Read the full official label on DailyMed.